¾Æµå¹Ýźũ¸² 15g ADVANTAN CREAM
Àü¹®ÀǾàǰ | »èÁ¦
¼öÀÔÀǾàǰ
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
Àü¹®
Èò»ö ³»Áö ´©¸£½º¸§ÇÑ »öÀ» ¶ì´Â Å©¸²
Á¦Á¶È¸»ç
Intendis Manufacturing S.p.A
ÆÇ¸Åȸ»ç
Çѱ¹¸Þ³ª¸®´Ï(ÁÖ)
Çã°¡Á¤º¸
Á¤»ó
(2006.11.24)
BIT ¾àÈ¿ºÐ·ù
¿Ü¿ë ½ºÅ×·ÎÀ̵å (Steroids : Skin & Mucous Membrane)
º¹ÁöºÎºÐ·ù
264[ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
674900092\0 ¿ø/15g/°³(2016.12.01) (ÇöÀç¾à°¡) \2,415 ¿ø/15g/°³(2016.01.01)(º¯°æÀü¾à°¡)
ATCÄÚµå
Methylprednisolone aceponate / D07AC14
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
°æÁúÁö¹æ ,
±Û¸®¼¼·Ñ¸ð³ë½ºÅ׾Ʒ¹ÀÌÆ®40-55 ,
±Û¸®¼¼¸°85% ,
µðºÎÆ¿È÷µå·Ï½ÃÅç·ç¿£ ,
¸¶Å©·Î°ñ½ºÅ׾Ʒ¹ÀÌÆ® ,
º¥Áú¾ËÄÚ¿Ã ,
¼¼Å佺Å׾Ƹ±¾ËÄÚ¿Ã ,
¼ÙƼÀÜ378 ,
¿¡µ¥Æ®»ê³ªÆ®·ý ,
¿Ã·¹»êµ¥½Ç ,
Á¤Á¦¼ö
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
674900092
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/15g/°³(2016.12.01) (ÇöÀç¾à°¡)
\2,415 ¿ø/15g/°³(2016.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
Èò»ö ³»Áö ´©¸£½º¸§ÇÑ »öÀ» ¶ì´Â Å©¸² [Á¦ÇüÁ¤º¸ È®ÀÎ]
Æ÷À塤À¯Åë´ÜÀ§
15g
ÁÖ¼ººÐÄÚµå
193433CCM
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
Çã°¡»çÇ× ¿ø¹®Á¶È¸
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
½ÀÁø(¾ÆÅäÇÇÇǺο°, ½É»ó¼º½ÀÁø µî)
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ÀÏ 1ȸ Àû´ç·®À» ȯºÎ¿¡ ¾ã°Ô ¹Ù¸¥´Ù. ¼ºÀÎÀÇ °æ¿ì 12ÁÖ, ¼Ò¾ÆÀÇ °æ¿ì´Â 4ÁÖ ÀÌ»ó °è¼ÓÇØ¼ »ç¿ëÇÏÁö ¾Ê´Â´Ù.
±Ý±â
1) ¼¼±Õ(°áÇÙ, ¸Åµ¶ µî)․Áø±Õ(ĵð´ÙÁõ, ¹é¼± µî)․¹ÙÀÌ·¯½º(´ë»óÆ÷Áø, ´Ü¼øÆ÷Áø, ¼öµÎ, Á¾µÎÁõ µî)․¹é½ÅÁ¢Á¾ÈÄÀÇ ÇǺÎÁúȯ․µ¿¹°(¿È, »ç¸é¹ßÀÌ µî)¼º ÇǺΰ¨¿°Áõ ȯÀÚ(Áõ»óÀÌ ¾Ç鵃 ¼ö ÀÖ´Ù)
2) ÀÌ ¾à ¶Ç´Â ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
3) °í¸· õ°øÀÌ ÀÖ´Â ½ÀÁø¼º ¿ÜÀ̵µ¿° ȯÀÚ(õ°øºÎÀ§ÀÇ Ä¡À¯Áö¿¬ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù)
4) ±Ë¾ç(º£Ã¼Æ®º´ Á¦¿Ü), Á¦2µµ ½ÉÀ缺 ÀÌ»óÀÇ È»ó․µ¿»ó ȯÀÚ(ÇǺÎÀç»ýÀÌ ¾ïÁ¦µÇ¾î Ä¡À¯°¡ Áö¿¬µÉ ¼ö ÀÖ´Ù)
5) ÀÔÁÖÀ§ÇǺο°, º¸Åë¿©µå¸§, ÁÖ»ç ȯÀÚ
6) 3¼¼ ÀÌÇÏÀÇ À¯¾Æ
½ÅÁßÅõ¿©
1) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¹× ¼öÀ¯ºÎ
2) À¯¡¤¼Ò¾Æ
3) °í·ÉÀÚ
ÀÌ»ó¹ÝÀÀ
1) ÇǺÎ
¨ç °¨¿°Áõ : ÇǺÎÀÇ ¼¼±Õ¼º(Àü¿°¼º ³ó°¡Áø, ¸ð³¶¿° µî) ¹× Áø±Õ¼º(ĵð´ÙÁõ, ¹é¼± µî) °¨¿°ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù[¹ÐºÀºØ´ë¹ý(ODT)ÀÇ °æ¿ì ³ªÅ¸³ª±â ½±´Ù]. ÀÌ¿Í °°Àº Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â ÀûÀýÇÑ Ç×±ÕÁ¦³ª Ç×Áø±ÕÁ¦ µîÀ» º´¿ëÇÏ°í ½Å¼ÓÈ÷ °³¼±µÇÁö ¾ÊÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
¨è ÀϹÝÀû ÇǺÎÁõ»ó : ¸ð³¶¿°, ºÎ½º·³, ÇǺÎÀÚ±Ø, ÀÚÅë, ¹ß¿, ÀÛ¿°¨, ¹ßÁø, ¹ßÀû, È«Á¶, °¡·Á¿ò, ÇǺΰÇÁ¶, ³óÆ÷¼ºÇǺο°, ¾Ë·¹¸£±â¼º Á¢ÃËÇǺο°, ¶¡¶ì, ÇÑÁø, »óó¾ÇÈ, ¿åâ, ³óÆ÷Áõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
¨é Àå±â ¿¬¿ë : ½ºÅ×·ÎÀ̵强 ¿©µå¸§, ½ºÅ×·ÎÀ̵强 ÇǺÎ(ÇǺÎÀ§Ãà, ¸ð¼¼Ç÷°üÈ®Àå, ÀÚ¹Ý), ½ºÅ×·ÎÀ̵强 ÁÖ»ç, ÀÔÁÖÀ§ÇǺο°(ÀÔÁÖÀ§․¾È¸éÀüü¿¡ È«¹Ý, ±¸Áø, ¸ð¼¼Ç÷°üÈ®Àå, µüÁö, Àμ³), ¾î¸°¼±(åà×÷àÐ)¾ç ÇǺκ¯È, ´Ù¸ð, ÇǺκ¯»ö, ¼±Á¶, ¼öÆ÷¼ºÇǺο°, ¾ÆÅäÇÇÇǺο°, ÇǺÎÃâÇ÷ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â õõÈ÷ »ç¿ë·®À» ÁÙ¿© ÄÚ¸£Æ¼ÄÚÀ̵带 ÇÔÀ¯ÇÏÁö ¾ÊÀº ¾àÀ¸·Î ¹Ù²Ù¾î »ç¿ëÇÑ´Ù.
2) ³»ºÐºñ°è : ´ë·® ¶Ç´Â Àå±â°£¿¡ °ÉÄ£ ±¤¹üÀ§ÇÑ »ç¿ë, ¹ÐºÀºØ´ë¹ý¿¡ ÀÇÇØ ÄÚ¸£Æ¼ÄÚÀ̵å Àü½Å Åõ¿©¿Í °°Àº ³úÇϼöü․ºÎ½ÅÇÇÁú°è ±â´ÉÀÇ ¾ïÁ¦¸¦ °¡Á®¿Ã ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
3) ´« : ¾È°ËÇǺο¡ »ç¿ë½Ã ¾È¾Ð »ó½Â, ³ì³»ÀåÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù. ´ë·® ¶Ç´Â Àå±â°£¿¡ °ÉÄ£ ±¤¹üÀ§ÇÑ »ç¿ë, ƯÈ÷ ¹ÐºÀºØ´ë¹ýÀ» »ç¿ëÇÒ °æ¿ì Èij¶ÇϹ鳻Àå, ³ì³»Àå µîÀ̳ªÅ¸³¯ ¼ö ÀÖ´Ù.
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Cµî±Þ
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Á¦Çüº° º¹¾àÁöµµ
[Å©¸²]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
MethylPrednisolone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Pharmacology
MethylPrednisolone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Methylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents.
Metabolism
MethylPrednisolone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)
Protein Binding
MethylPrednisolone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 78%
Half-life
MethylPrednisolone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1-3 hours
Absorption
MethylPrednisolone¿¡ ´ëÇÑ Absorption Á¤º¸ Oral bioavailability 80-99%
Pharmacokinetics
MethylPrednisolone aceponateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£°ú È¿°úÁö¼Ó½Ã°£Àº Åõ¿©°æ·Î¿¡ µû¶ó ´Ù¸¥´Ù.
ºÐÆ÷: Vd : 0.7L/kg
¹Ý°¨±â : 3¡3.5½Ã°£
Methylprednisolone sodium succinate´Â ¹°¿¡ ´ëÇÑ ¿ëÇØ¼ºÀÌ ¸Å¿ì Å©±â ¶§¹®¿¡ Á¤¸ÆÁֻ糪 ±ÙÀ°Áֻ縦 ÇÏ´Â °æ¿ì È¿°ú°¡ ºü¸£°Ô ³ªÅ¸³´Ù; Methylprednisolone acetate´Â ¿ëÇØ¼ºÀÌ ³·±â ¶§¹®¿¡ ±ÙÀ°ÁÖ»ç½Ã Áö¼ÓÀûÀÎ È¿°ú¸¦ ³ªÅ¸³½´Ù.
Biotransformation
MethylPrednisolone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
Toxicity
MethylPrednisolone¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 =2000 mg/kg (orally in rat)
Drug Interactions
MethylPrednisolone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Drug Target
[Drug Target]
Description
MethylPrednisolone¿¡ ´ëÇÑ Description Á¤º¸ A prednisolone derivative with similar anti-inflammatory action. [PubChem]
Dosage Form
MethylPrednisolone¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Powder IntramuscularPowder IntravenousPowder, for solution IntravenousSuspension IntramuscularTablet Oral
Drug Category
MethylPrednisolone¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic AgentsAnti-inflammatory AgentsAntiemeticsGlucocorticoidsNeuroprotective Agents
Smiles String Canonical
MethylPrednisolone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1CC2C3CCC(O)(C(=O)CO)C3(C)CC(O)C2C2(C)C=CC(=O)C=C12
Smiles String Isomeric
MethylPrednisolone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
InChI Identifier
MethylPrednisolone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
Chemical IUPAC Name
MethylPrednisolone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
Drug-Induced Toxicity Related Proteins
METHYLPREDNISOLONE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein :Tyrosine aminotransferaseDrug :methylprednisolone Toxicity :liver toxicity. [¹Ù·Î°¡±â] Replated Protein :P-selectin Drug :methylprednisolone Toxicity :chronic idiopathic thrombocytopenic purpura (ITP). [¹Ù·Î°¡±â] Replated Protein :Interleukin-6 Drug :methylprednisolone Toxicity :chronic idiopathic thrombocytopenic purpura (ITP). [¹Ù·Î°¡±â] Replated Protein :Glucocorticoid receptorDrug :methylprednisolone Toxicity :liver toxicity. [¹Ù·Î°¡±â] Replated Protein :Thrombopoietin (TPO)Drug :methylprednisolone Toxicity :chronic idiopathic thrombocytopenic purpura (ITP). [¹Ù·Î°¡±â] METHYLPREDNISOLONE (MPL) ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein :Glucocorticoid receptorDrug :methylprednisolone (MPL) Toxicity :liver toxicity. [¹Ù·Î°¡±â] Replated Protein :Tyrosine aminotransferaseDrug :methylprednisolone (MPL) Toxicity :liver toxicity. [¹Ù·Î°¡±â] PREDNISOLONE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein :DNA topoisomerase 1Drug :prednisolone Toxicity :appearance of apoptotic cells. [¹Ù·Î°¡±â]
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-07-25
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ